One of Wall Street’s most high-profile hedge funds pushes Alexion's CEO to the auction block — and he's not budging
Fresh off buying Barnes & Noble and prodding AT&T with some heavy-handed criticism after picking up a $3.2 billion stake in the company, the activist — and supremely high profile — hedge fund Elliott Management has stepped up with some M&A advice for Alexion’s management team.
And the execs on the team $ALXN are giving them a polite — but very firm — stiff arm Friday morning.
In a release out early Friday, the big biotech said that the Elliott team had been in touch to encourage them to sell the company. But that’s not on the agenda.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,400+ biopharma pros reading Endpoints daily — and it's free.